Moutafi, M.K. (Myrto K.)

Filtering

20221

Settings

Author search.filters.isAuthorOfPublication.442df6b1-4fdc-4008-9623-b3f62e27346e

Search Results

Now showing 1 - 1 of 1
  • Thumbnail Image
    Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small- cell lung cancer
    (BMJ, 2022) Martínez-Morilla, S. (Sandra); Zugazagoitia, J. (Jon); Moutafi, M.K. (Myrto K.); Molero, M. (Magdalena); Rimm, D.L. (David L.); Adradas, V. (Vera); Castro-Labrador, L. (Laura); Montuenga-Badia, L.M. (Luis M.); Vathiotis, I.A. (Ioannis A.); Orive-Mauleón, D. (Daniel); Gavrielatou, N. (Niki); Herbst, R.S. (Roy S.); Valencia, K. (Karmele); Paz-Ares, L. (Luis); Ruiz-de-Garibay, G. (Gorka); Baena, J. (Javier); Calvo-González, A. (Alfonso); Schalper, K.A. (Kurt A.); Ponce-Aix, S. (S.)
    Most patients with advanced non-small-cell lung cancer (NSCLC) fail to derive significant benefit from programmed cell death protein-1 (PD-1) axis blockade, and new biomarkers of response are needed. In this study, we aimed to discover and validate spatially resolved protein markers associated with sensitivity to PD-1 axis inhibition in NSCLC.